http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1162982-A2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d7e470e09803bd6bf24b2fd176109dd
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-711
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2000-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77e45a3344a184e2c4402d5ae748efe2
publicationDate 2001-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-1162982-A2
titleOfInvention Use of stabilised oligonucleotides for preparing a medicine with antitumour activity
abstract The invention concerns the use of stabilized oligonucleotides comprising at least an octamer motif of the type: 5′-purine-purine-CG-pyrimdine-pyrimidine-X1X2-3′ wherein the pair X1-X2 is AT, AA, CT or TT, for preparing a medicine with antitumour activity.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020136235-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022148736-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017191147-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019170820-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018234506-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012160153-A1
priorityDate 1999-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP83348
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35034
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35048
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135926519
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396023
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00761
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35049
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423408
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228258154
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35050
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21946428
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57091925
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228258157
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID28280
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP81071
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35051
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00764
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP24664
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP00775
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22057568
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO97399
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP23916
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226401396
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP19799
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP51588
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID75233
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ59149
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP35396
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ03181
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129016856
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP70059
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5773

Total number of triples: 56.